Lilly/Amylin Submit Exenatide For Type 2 Diabetes; Could Be Insulin Alternative

Firms will likely target patients on oral diabetes medications who would normally take insulin. Priority review for the first-in-class incretin mimetic would set a user fee goal date of Dec. 30.